Rare Adverse Events Related to Nivolumab, an Immune Checkpoint Inhibitor: A Case Series

Immune checkpoint inhibitors are a novel class of immunotherapy drugs that have improved the prognosis of melanoma, renal cell carcinoma, non-small cell lung cancer, urothelial carcinoma, and various other solid tumors. Nivolumab is an immune checkpoint inhibitor that acts by inhibiting programmed d...

Descripción completa

Detalles Bibliográficos
Autores principales: Ganta, Nagapratap, Alnabwani, Dina, Keating, Shawn, Patel, Vraj, Bommu, Veera Jayasree Latha, Dawoud, Rand, Cheriyath, Pramil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Endocrinology/Diabetes/Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8916979/
https://www.ncbi.nlm.nih.gov/pubmed/35295363
http://dx.doi.org/10.7759/cureus.22070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8916979/
https://www.ncbi.nlm.nih.gov/pubmed/35295363
http://dx.doi.org/10.7759/cureus.22070

Ejemplares similares